Publications

2018

  1. Gili Ben-Nissan; Shay Vimer; Shira Warszawski et al. (2018). Rapid characterization of secreted recombinant proteins by native mass spectrometry.  Communications biology. 1.  Abstract [All authors]
  2. Hadas Cohen-Dvashi; Itay Kilimnik; Ron Diskin (2018). Structural basis for receptor recognition by Lujo virus.  Nature Microbiology. 3:(10)1153-1160.  Abstract
  3. Nadav Elad; Szilvia Baron; Yoav Peleg; Shira Albeck; Jacob Grunwald; Gal Raviv; Zippora Shakked; Oren Zimhony; Ron Diskin (2018). Structure of Type-I Mycobacterium tuberculosis fatty acid synthase at 3.3 angstrom resolution.  Nature Communications. 9.  Abstract
  4. Szilvia Baron; Yoav Peleg; Jacob Grunwald et al. (2018). Expression of a recombinant, 4 '-Phosphopantetheinylated, active M-tuberculosis fatty acid synthase I in E-coli.  PLoS One. 13:(9)  Abstract [All authors]
  5. Andriy Kryshtafovych; Reinhard Albrecht; Arnaud Basle et al. (2018). Target highlights from the first post-PSI CASP experiment (CASP12, May-August 2016).  Proteins-Structure Function And Bioinformatics. 86:27-50.  Abstract [All authors]

2017

  1. Amir Shimon; Orly Shani; Ron Diskin (2017). Structural Basis for Receptor Selectivity by the Whitewater Arroyo Mammarenavirus.  Journal of Molecular Biology. 429:(18)2825-2839.  Abstract
  2. Hadar Israeli; Hadas Cohen-Dvashi; Anastasiya Shulman; Amir Shimon; Ron Diskin (2017). Mapping of the Lassa virus LAMP1 binding site reveals unique determinants not shared by other old world arenaviruses.  PLoS Pathogens. 13:(4)  Abstract

2016

  1. Hadas Cohen-Dvashi; Hadar Israeli; Orly Shani; Aliza Katz; Ron Diskin (2016). Role of LAMP1 Binding and pH Sensing by the Spike Complex of Lassa Virus.  Journal of Virology. 90:(22)10329-10338.  Abstract

2015

  1. Hadas Cohen-Dvashi; Nir Cohen; Hadar Israeli; Ron Diskin (2015). Molecular Mechanism for LAMP1 Recognition by Lassa Virus.  Journal of Virology. 89:(15)7584-7592.  Abstract

2014

  1. Gilad Ofek; Ron Diskin (2014). Expanding the breadth of an HIV-1 vaccine.  Science. 346:(6215)1290-1291.
  2. M Shingai; OK Donau; RJ Plishka et al. (2014). Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.  Journal of Experimental Medicine. 211:(10)2061-2074.  Abstract [All authors]

2013

  1. Ron Diskin; Florian Klein; Joshua A. Horwitz et al. (2013). Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies.  Journal of Experimental Medicine. 210:(6)1235-1249.  Abstract [All authors]
  2. Louise Scharf; Anthony P., Jr. West; Han Gao; Terri Lee; Johannes F. Scheid; Michel C. Nussenzweig; Pamela J. Bjorkman; Ron Diskin (2013). Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.  Proceedings of the National Academy of Sciences of the United States of America. 110:(15)6049-6054.  Abstract
  3. Florian Klein; Ron Diskin; Johannes F. Scheid et al. (2013). Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization.  Cell. 153:(1)126-138.  Abstract [All authors]
  4. Sam Hoot; Andrew T. McGuire; Kristen W. Cohen et al. (2013). Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs.  PLoS Pathogens. 9:(1)  Abstract [All authors]

2012

  1. Florian Klein; Ariel Halper-Stromberg; Joshua A. Horwitz et al. (2012). HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.  Nature. 492:(7427)118-+.  Abstract [All authors]
  2. John Pietzsch; Henning Gruell; Stylianos Bournazos et al. (2012). A mouse model for HIV-1 entry.  Proceedings of the National Academy of Sciences of the United States of America. 109:(39)15859-15864.  Abstract [All authors]
  3. Anthony P., Jr. West; Ron Diskin; Michel C. Nussenzweig; Pamela J. Bjorkman (2012). Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.  Proceedings of the National Academy of Sciences of the United States of America. 109:(30)E2083-E2090.  Abstract

2011

  1. Ron Diskin; Johannes F. Scheid; Paola M. Marcovecchio et al. (2011). Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design.  Science. 334:(6060)1289-1293.  Abstract [All authors]
  2. Johannes F. Scheid; Hugo Mouquet; Beatrix Ueberheide et al. (2011). Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding.  Science. 333:(6049)1633-1637.  Abstract [All authors]
  3. Netanel Tzarum; Ron Diskin; David Engelberg; Oded Livnah (2011). Active Mutants of the TCR-Mediated p38 alpha Alternative Activation Site Show Changes in the Phosphorylation Lip and DEF Site Formation.  Journal of Molecular Biology. 405:(5)1154-1169.  Abstract

2010

  1. Ron Diskin; Paola M. Marcovecchio; Pamela J. Bjorkman (2010). Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity.  Nature Structural & Molecular Biology. 17:(5)608-U109.  Abstract

2008

  1. Tal I. Arnon; Jens T. Kaiser; Anthony P., Jr. West; Rich Olson; Ron Diskin; Birgit C. Viertlboeck; Thomas W. Goebel; Pamela J. Bjorkman (2008). The crystal structure of CHIR-AB1: A primordial avian classical fc receptor.  Journal of Molecular Biology. 381:(4)1012-1024.  Abstract
  2. Ron Diskin; David Engelberg; Oded Livnah (2008). A novel lipid binding site formed by the MAP kinase insert in p38 alpha.  Journal of Molecular Biology. 375:(1)70-79.  Abstract

2007

  1. Ron Diskin; David Engelberg; Oded Livnah (2007). High-resolution diffracting crystals of intrinsically active p38 alpha MAP kinase: a case study for low-throughput approaches.  Acta Crystallographica Section D-Biological Crystallography. 63:260-265.  Abstract
  2. Michal Avitzour; Ron Diskin; Bilha Raboy; Nadav Askari; David Engelberg; Oded Livnah (2007). Intrinsically active variants of all human p38 isoforms.  FEBS Journal. 274:(4)963-975.  Abstract
  3. Nadav Askari; Ron Diskin; Michal Avitzour; Ricardo Capone; Oded Livnah; David Engelberg (2007). Hyperactive variants of p38 alpha induce, whereas hyperactive variants of p38 gamma suppress, activating protein 1-mediated transcription.  Journal of Biological Chemistry. 282:(1)91-99.  Abstract
  4. Ron Diskin; Mario Lebendiker; David Engelberg; Oded Livnah (2007). Structures of p38 alpha active mutants reveal conformational changes in L16 loop that induce autophosphorylation and activation.  Journal of Molecular Biology. 365:(1)66-76.  Abstract

2006

  1. Yael Friedmann; Anat Shriki; Estelle R. Bennett; Stella Golos; Ron Diskin; Irit Marbach; Eyal Bengal; David Engelberg (2006). JX401, A p38 alpha inhibitor containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast.  Molecular Pharmacology. 70:(4)1395-1405.  Abstract
  2. Nadav Askari; Ron Diskin; Michal Avitzour; Gilad Yaakov; Oded Livnah; David Engelberg (2006). MAP-quest: Could we produce constitutively active variants of MAP kinases?.  Molecular and Cellular Endocrinology. 252:(2-Jan)231-240.  Abstract

2004

  1. Ron Diskin; N Askari; R Capone; D Engelberg; O Livnah (2004). Active mutants of the human p38 alpha mitogen-activated protein kinase.  Journal of Biological Chemistry. 279:(45)47040-47049.  Abstract